Research study Program year 2020 Source: CMS Open Payments

PH II Placebo Controlled of Mtig7192a and Atezo in Nsclc

Research payments

$1,690,000

315 payments

Through program year 2020, $1,690,000 in research payments was reported against PH II Placebo Controlled of Mtig7192a and Atezo in Nsclc, across 315 payments.

Paid by (largest first): Genentech, Inc.; F. Hoffmann-La Roche AG
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$574,830	126
2019	Research	$1,115,170	189

Breakdown

Who paid Research payments · program years 2019–2020

Genentech, Inc. $1,689,705 313 payments
F. Hoffmann-La Roche AG $295 2 payments

Who received the money Research payments · program years 2019–2020

Sarah Cannon Research Organisation paid for research $591,378 96 payments
US Oncology Research, Inc. Organisation paid for research $253,117 41 payments
Sarah Cannon Research Institute LLC Organisation paid for research $244,038 22 payments
Virginia Cancer Specialists Organisation paid for research $102,609 2 payments
US Oncology Research LLC Organisation paid for research $92,288 23 payments
Arizona Oncology Organisation paid for research $88,407 4 payments
Karmanos Cancer Hospital Teaching hospital · MI $87,425 72 payments
Sarah Cannon Researchinstitute LLC Organisation paid for research $53,041 5 payments
Kumc Research Institute INC Organisation paid for research $52,559 20 payments
Oncology/Hematology Associates Organisation paid for research $48,681 14 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.